Bafna Pharma.

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "125.10",
    "chg": 5.95,
    "chgp": "4.99%",
    "dir": 1,
    "prev_price": "119.15",
    "mcapval": "295.94 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE878I01022",
    "curr_date": "Mar 20",
    "curr_time": "",
    "bse_nse_vol": "11.52 k",
    "exc_status": "Active",
    "traded_date": "Mar 20, 2026",
    "traded_date_str": "2026 03 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3903008",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3903008.png",
        "date": "2026-03-20 11:00:08",
        "description": "At Rs 126.52, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 19 Mar 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-momentum-3900059",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3900059.png",
        "date": "2026-03-19 10:00:13",
        "description": "Bafna Pharmaceuticals Ltd (Stock ID: 852453) surged to its upper circuit limit on 19 Mar 2026, closing at ₹120.5, marking a maximum daily gain of 4.99%. This sharp rally was driven by robust buying interest, with the stock outperforming its sector and broader market indices despite a subdued market environment."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3898425",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3898425.png",
        "date": "2026-03-18 10:00:17",
        "description": "Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 18 Mar 2026, reflecting robust buying interest and a maximum daily gain of 4.99%. The micro-cap pharmaceutical stock outperformed its sector and broader market indices, signalling renewed investor enthusiasm despite its Strong Sell mojo grade."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3896134",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3896134.png",
        "date": "2026-03-17 10:00:13",
        "description": "Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 17 Mar 2026, reflecting robust investor demand and significant buying momentum. The stock closed at ₹109.31, marking a maximum daily gain of 4.99%, outperforming its sector and broader market indices amid heightened trading activity and regulatory freeze on further price movement."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3894282",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_stocks_hitting_upper_circuit_3894282.png",
        "date": "2026-03-16 15:00:07",
        "description": "Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 16 Mar 2026, registering a maximum daily gain of 4.99% to close at ₹104.11. This sharp rally was driven by robust buying interest despite the stock opening with a gap down, signalling a notable reversal after three consecutive days of decline in a challenging micro-cap pharmaceuticals sector."
      },
      {
        "title": "Bafna Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-downgraded-to-strong-sell-amid-technical-and-financial-weakness-3892860",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_mojoScore_3892860.png",
        "date": "2026-03-16 08:12:12",
        "description": "Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 March 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite a modest one-year stock return outperforming the broader market, the company faces significant challenges across quality, valuation, financial trends, and technical parameters that have prompted a reassessment of its investment appeal."
      },
      {
        "title": "Bafna Pharmaceuticals Drops 12.21%: Death Cross and Lower Circuit Mark a Bearish Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-drops-1221-death-cross-and-lower-circuit-mark-a-bearish-week-3891060",
        "imagepath": "",
        "date": "2026-03-14 13:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Mar 09:</strong> Lower circuit hit amid heavy selling pressure (Rs.106.59)</p>\n                    <p><strong>Mar 13:</strong> Death Cross formation signalling bearish trend (Rs.98.15)</p>\n                    <p><strong>Week Close:</strong> Rs.98.15 (-12.21%) vs Sensex (-4.87%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.111.80</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.98.15</div><div class=\"stat-change negative\">-12.21%</div></div>\n                    <div class=\"stat-it..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Forms Death Cross, Signalling Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-forms-death-cross-signalling-bearish-trend-ahead-3889962",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_dealthcross_3889962.png",
        "date": "2026-03-13 19:00:24",
        "description": "Bafna Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s long-term strength amid ongoing sector challenges."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3884847",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BafnaPharmaceut_mojoScore_3884847.png",
        "date": "2026-03-11 10:10:33",
        "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 285,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Feb-2026",
      "details": "Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine-Months ended December 31 2025 as published in Business Standard and Makkal Kural on February 13 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome For The Board Meeting Held On 11/02/2026",
      "datetime": "11-Feb-2026",
      "details": "The Board of Directors of the Company in the Meeting held on February 11 2026 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Nine-Months ended on December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2025",
      "datetime": "11-Feb-2026",
      "details": "The Board of Directors of the Company in their Meeting held on February 11 2026 has inter-alia considered and approved the Un-Audited Financial Results of the Company along with the Limited Review Report for the Quarter and Nine Months ended on December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent

2026-03-20 11:00:08

At Rs 126.52, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 19 Mar 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Momentum

2026-03-19 10:00:13

Bafna Pharmaceuticals Ltd (Stock ID: 852453) surged to its upper circuit limit on 19 Mar 2026, closing at ₹120.5, marking a maximum daily gain of 4.99%. This sharp rally was driven by robust buying interest, with the stock outperforming its sector and broader market indices despite a subdued market environment.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-03-18 10:00:17

Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 18 Mar 2026, reflecting robust buying interest and a maximum daily gain of 4.99%. The micro-cap pharmaceutical stock outperformed its sector and broader market indices, signalling renewed investor enthusiasm despite its Strong Sell mojo grade.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-03-17 10:00:13

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 17 Mar 2026, reflecting robust investor demand and significant buying momentum. The stock closed at ₹109.31, marking a maximum daily gain of 4.99%, outperforming its sector and broader market indices amid heightened trading activity and regulatory freeze on further price movement.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-03-16 15:00:07

Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 16 Mar 2026, registering a maximum daily gain of 4.99% to close at ₹104.11. This sharp rally was driven by robust buying interest despite the stock opening with a gap down, signalling a notable reversal after three consecutive days of decline in a challenging micro-cap pharmaceuticals sector.

Read full news article

Bafna Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Weakness

2026-03-16 08:12:12

Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 March 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite a modest one-year stock return outperforming the broader market, the company faces significant challenges across quality, valuation, financial trends, and technical parameters that have prompted a reassessment of its investment appeal.

Read full news article

Bafna Pharmaceuticals Drops 12.21%: Death Cross and Lower Circuit Mark a Bearish Week

2026-03-14 13:00:05

Key Events This Week

Mar 09: Lower circuit hit amid heavy selling pressure (Rs.106.59)

Mar 13: Death Cross formation signalling bearish trend (Rs.98.15)

Week Close: Rs.98.15 (-12.21%) vs Sensex (-4.87%)

Week Open

Rs.111.80

Week Close

Rs.98.15

-12.21%

Read full news article

Bafna Pharmaceuticals Ltd Forms Death Cross, Signalling Bearish Trend Ahead

2026-03-13 19:00:24

Bafna Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s long-term strength amid ongoing sector challenges.

Read full news article

Bafna Pharmaceuticals Ltd is Rated Sell

2026-03-11 10:10:33

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News